Primary tumor location found to impact prognosis and response to therapy in patients with metastatic colorectal cancer

Abstract

Patients with mCRC with a left‐sided primary tumor carry a better prognosis than patients with tumors originating on the right side. Adding cetuximab to chemotherapy improves outcomes for patients with left‐sided tumors, but not for those with right‐sided ones. Side of origin should be considered when deciding on therapeutic regimens for patients with mCRC.